Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "Human"

1142 News Found

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%
News | May 28, 2021

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%

The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year


Remdesivir demand was exaggerated: Dr. Sharvil Patel
News | May 28, 2021

Remdesivir demand was exaggerated: Dr. Sharvil Patel

Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines


Zydus and TLC sign agreement to market Liposomal Amphotericin B in India
News | May 26, 2021

Zydus and TLC sign agreement to market Liposomal Amphotericin B in India

With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage


Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval


Panacea Biotec to manufacture 10 crore doses per year of Sputnik V
News | May 24, 2021

Panacea Biotec to manufacture 10 crore doses per year of Sputnik V

First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer


Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency
News | May 21, 2021

Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency

Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.


Cipla signs agreement with Merck for Molnupiravir
News | April 29, 2021

Cipla signs agreement with Merck for Molnupiravir

Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19


Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
Biotech | April 28, 2021

Biocon and Viatris receive EC approval for Biosimilar Bevacizumab

The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer


Lonza and Immunitas announce manufacturing agreement
News | April 18, 2021

Lonza and Immunitas announce manufacturing agreement

Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies


Merck publishes sustainability report for 2020
News | April 13, 2021

Merck publishes sustainability report for 2020

The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.